Physician profile
Paramjit Singh
NPI 1740392133
$3,668.24
in general payments reported to CMS, 2019-2025
24 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Behavioral Neurology & Neuropsychiatry provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $562 · 2021: $591 · 2022: $422 · 2023: $857 · 2024: $630 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.58 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,538.17 | 2020-2025 | Ubrelvy, Qulipta |
| Alphatec Spine, INC | $329.76 | 2020-2021 | |
| Allergan, INC. | $252.79 | 2019-2020 | |
| Abbott Laboratories | $190.80 | 2023 | Penta |
| Biogen, INC. | $185.68 | 2020-2025 | Vumerity, Tysabri |
| Neurocrine Biosciences, INC. | $155.90 | 2020-2023 | Ingrezza |
| Lilly USA, LLC | $155.31 | 2019-2024 | Amyvid, Kisunla |
| W. L. Gore & Associates, INC. | $147.99 | 2023 | Gore Cardioform Septal Occluder |
| Amneal Pharmaceuticals LLC | $116.72 | 2020-2024 | Rytary |
| Covidien Lp | $103.06 | 2019 | |
| Ucb, INC. | $83.44 | 2019-2025 | Rystiggo |
| Amgen INC. | $70.44 | 2022 | |
| Acadia Pharmaceuticals INC | $59.25 | 2020-2022 | |
| Mdd US Operations, LLC | $47.13 | 2022-2024 | Gocovri |
| Kyowa Kirin, INC. | $38.97 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $38.71 | 2020 | |
| Supernus Pharmaceuticals, INC. | $31.44 | 2020 | |
| Genentech USA, INC. | $23.47 | 2023 | Ocrevus |
| Celgene Corporation | $22.26 | 2022 | |
| Argenx US, INC. | $19.66 | 2024 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $17.55 | 2024 | Xeomin |
| Adamas Pharmaceuticals, INC. | $15.14 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.44 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paramjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.